PDS Biotech builds pipeline with rights to novel immunotherapy

3 January 2023

A new development and licensing deal with Germany’s Merck KGaA (MRK: DE) will augment the pipeline of immunotherapy specialist PDS Biotechnology (Nasdaq: PDSB).

The New Jersey, USA-based firm is working on a pipeline of targeted immunotherapies for cancer and infectious diseases, which will now include the interleukin (IL)-12 fusion protein M9241.

Drawn by the potential of the candidate to enhance the cancer-targeting effects of T-cells, PDS has secured an exclusive license to the candidate, in return for financial commitments including an upfront consideration of $5 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK